Altimmune, Inc. (ALT)

Altimmune, Inc. (ALT) is a healthcare company (biotechnology) based in the United States. The share price is $1.55, down 0.96% on the day, which values the company at $300.64M. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.

Key facts

Share price
$1.55−0.96% today
Market value
$300.64M
Funk Score
13/100
200-week average
$5.4271% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Altimmune, Inc. in more detail

ALT trades at -2.2× next year's expected earnings, 11563.1× sales. It sits 71% below its 200-week average of $5.42.

Over the last five fiscal years Altimmune, Inc. has compounded revenue -65.3% a year. Its Funk Score is 13 out of 100 (financial strength 3.8, profitability 0.0, growth 1.3, value 0.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Share count keeps rising.

2 of the superinvestors tracked here hold ALT, including Peter Kolchinsky (0.2% of the portfolio), Andreas Halvorsen (0.1% of the portfolio).

Superinvestors holding ALT

2 of the investors tracked here report a position in their latest 13F filing.

Altimmune, Inc. (ALT): questions and answers

What is ALT's PEG ratio?

Altimmune, Inc.'s PEG ratio is 32.62 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Altimmune, Inc.'s market cap?

Altimmune, Inc. is valued at $300.64M at a share price of $1.55.

Is ALT above its 200-week moving average?

No. ALT is 71.5% below its 200-week average of $5.42. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Altimmune, Inc. growing?

Over the last five fiscal years Altimmune, Inc.'s revenue grew -65.3% a year.

Does ALT pay a dividend?

Altimmune, Inc. does not currently pay a regular dividend.

Which famous investors own ALT?

In their latest quarterly filings, Peter Kolchinsky (0.2% of the portfolio), Andreas Halvorsen (0.1% of the portfolio) hold ALT. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Altimmune, Inc. (ALT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ALT

Underlying data: Yahoo Finance; company filings with the SEC.